Managing skin toxicities related to panitumumab

Hagit Bergman, Tara Walton, Ryan Del Bel, Jack T. Seki, Ava Rafii, Wei Xu, Gideon Koren, Neil Shear, Monika K. Krzyzanowska, Doris Howell, Geoffrey Liu

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


Background: Dermatologic toxicities from targeted agents such as panitumumab can interfere with cancer treatment. Objective: We sought to evaluate the rash assessment and management in a consecutive patient cohort who received panitumumab for colorectal cancer treatment. Methods: This was a retrospective chart review. Results: Skin toxicity, consisting of papulopustular rash, was experienced by 32 of 34 patients. The majority (85%) developed the rash by the end of the second infusion cycle. Patients presented with a mild (41%), moderate (38%), and severe (21%) rash, and progressed to an extensive rash without appropriate treatment. A grading system was used for 65% of patients to document severity. Limitations: Small sample size limited power in analysis. Rash severity had to be inferred based on rash description and management in 11 of the patients. Conclusion: Dermatologic toxicities related to panitumumab are common; however, theway they are reported andmanaged variesamongphysicians.Topreventprogression, toxicitiesmust be assessedandtreatedearly and aggressively, according to severity grading. Dermatologists could aid oncologists in choosing the best management strategies. ( J Am Acad Dermatol 2014;71:754-9.).

Original languageEnglish
Pages (from-to)754-759
Number of pages6
JournalJournal of the American Academy of Dermatology
Issue number4
StatePublished - 2014
Externally publishedYes


  • Common Toxicity Criteria for Adverse Events
  • Epidermal growth factor receptor inhibitors
  • Panitumumab
  • Papulopustular rash
  • Skin toxicity


Dive into the research topics of 'Managing skin toxicities related to panitumumab'. Together they form a unique fingerprint.

Cite this